Category: Stock Market

The Tesoro Gold Ltd (ASX: TSO) share price is storming higher on Wednesday following the release of a company announcement.

At the time of writing, shares are advancing 30.56% into the green having bounced from yesterday’s 52-week lows, and now rest at 4.7 cents apiece.

What did Tesoro announce?

The company advised that its new drill program at the El Zorro Gold Project has intersected gold. intercepts of 434.60m at 1.22g/t Au from 15.40m.

Resource was found at the company’s Ternera gold deposit that is located at El Zorro. The drill program has revealed multiple high-grade zones within the intercept.

These results could potentially increase the gold grade throughout the deposit as well.

Following the discovery, Tesoro says that it now has numerous potential gold-bearing targets that it intends to explore.

Speaking on the results, Tesoro Managing Director, Zeff Reeves said:

This is a phenomenal result demonstrating the consistency of gold mineralisation within the host El
Zorro Tonalite intrusions. Hole ZDDH0297 shows multiple high-grade zones within the broader
intercept, potentially increasing gold grade throughout the deposit.

This phase of drilling at Ternera is focussed on improving the classification and expanding the existing 1.1 Moz Resource. We believe Ternera will continue to grow with additional drilling with the Deposit remaining open in all directions.

Drilling continues at the Ternera site. To date, 7 holes for a total depth of 3,275m have been completed. The company is awaiting assays for 5 holes “which will be announced in due course”.

After racing to previous highs back in 2021, the Tesoro share price is down 55% in the past 12 months of trade.

The post Guess which ASX mining share just rocketed 31% on a new gold strike appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#43B02A”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#43B02A”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• Is Alphabet stock a buy after Q2 earnings?
• Could the Pilbara Minerals share price really offer more than 50% upside in FY23?
• Net loss doubles in FY22, so what’s with the Imugene share price today?
• Why is the 4DMedical share price rocketing 20% on Wednesday?
• Why is the Best & Less share price crashing 15% on Wednesday?

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/HXWzZCB

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

This has been a busy year for Alphabet Inc. (NASDAQ: GOOG) (NASDAQ: GOOGL). The company has acquired two companies in the cybersecurity space and most recently completed a stock split. Alphabet recently reported second-quarter 2022 earnings and the results were mixed. Though the search and cloud segments were big winners, some investors may be worrying about how the internet giant can sidestep its competition as well as combat macroeconomic factors such as lingering inflation. Let’s dig into the Q2 earnings and analyze if Alphabet appears to be a good buy, or if investors should look elsewhere.

Is the slowdown in revenue a cause for concern?

For the second quarter, which ended on June 30, Alphabet generated $69.7 billion in total revenue. This was an increase of 13% year over year. By comparison, Alphabet grew revenue by a staggering 62% year over year during the same period in 2021. Given the slowdown in top-line growth, investors may be quick to sell and search for new investment opportunities. However, the most prudent thing investors can do is look at where Alphabet may be experiencing levels of stagnation or even declining growth, and which areas are performing well. The table below illustrates Alphabet’s revenue streams during Q2 2022, and percentage changes year over year.

Revenue Segment	Q2 2021	Q2 2022	% Change
Google Search	$35,845	$40,689	14%
YouTube Ads	$7,002	$7,340	5%
Google Network	$7,597	$8,259	9%
Total Google Advertising	$50,444	$56,288	12%
Other	$6,623	$6,553	(1%)
Total Google Services	$57,067	$62,841	10%
Google Cloud	$4,628	$6,276	36%
Other Bets	$192	$193	1%
Hedging Gains (Losses)	($7)	$375	NM
Total Revenue	$61,880	69,685	13%

Data source: Alphabet Q2 2022 Earnings Press Release. The financial figures above are presented in millions of U.S. dollars. NM = non-material.

The table above shows that the search and cloud segments increased 14% and 36% respectively. Advertising from YouTube only increased only 5%. During Q2 2021, YouTube advertising revenue increased by 84%. The massive slowdown in growth is, in part, driven by competing applications such as TikTok. It is important to note that Alphabet has rolled out its own derivative of TikTok, YouTube Shorts. However, management noted during the earnings call that YouTube Shorts is in early development and not yet fully monetized. Additionally, investors learned that vendors have been slashing advertising budgets across different industries due to uncertainty around the broader economic environment, thereby posing a systemic risk to Alphabet’s ad revenue stream.

Given that advertising budgets and lingering inflation do not have a clear path to subside, investors may want to focus on other areas of Alphabet, namely cloud computing.

Are the acquisitions paying off?

Earlier this year Alphabet acquired two cybersecurity companies, Mandiant and Siemplify The strategic rationale behind these transactions was that Alphabet would integrate the new products and services into its Google Cloud Platform. This was a direct effort to combat cloud behemoth Amazon.com, Inc. (NASDAQ: AMZN), as well as cloud and cybersecurity competitor Microsoft Corporation (NASDAQ: MSFT). 

For the quarter that ended June 30, Alphabet reported $6.3 billion in cloud revenue, up 36% year over year. To put this into context, during Q2 2021 Google Cloud was operating at roughly $18.5 billion in annual run-rate revenue. Only one year later, Google Cloud is now a $25.1 billion annual run-rate-revenue business. While this revenue growth is impressive, it certainly has come at a cost. Google Cloud’s operating loss was $858 million for Q2 2022, compared to a loss of $591 million during Q2 2021. Despite robust top-line growth, Alphabet has yet to turn a profit on its cloud platform. By comparison, Amazon’s cloud business operates at a profit, with margins expanding from 28% in Q2 2021 to 29% in Q2 2022.

Keep an eye on valuation

From its stock split in early July, Alphabet stock is up roughly 5%. With cash on hand of $17.9 billion and free cash flow of $12.6 billion, it’s difficult to make a case that Alphabet is in financial trouble. However, Alphabet is at a critical juncture where it is seeing competition from much smaller players, as well as big tech peers.

Perhaps investors should be looking at Alphabet as a growth company. Given its cloud business has a lot of room to grow, and that economic pain points like inflation will not last forever, it could be argued that Alphabet will generate meaningful growth in the years ahead. While the stock has been somewhat muted since the split, now may be a decent time to dollar-cost average or initiate a long-term position while keeping a keen eye on upcoming earnings reports. While Alphabet is not yet out of the woods, there are several reasons to believe that now is a good time to buy the stock.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

The post Is Alphabet stock a buy after Q2 earnings? appeared first on The Motley Fool Australia.

(function() { function setButtonColorDefaults(param, property, defaultValue) { if( !param || !param.includes(‘#’)) { var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0]; button.style[property] = defaultValue; } } setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’); setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’); setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’); })()

More reading

• Why the Amazon share price slumped on Tuesday
• Why Amazon’s latest green hydrogen partnership is a big deal
• 2 genius reasons to buy Amazon stock today
• Does this make Amazon stock a buy?
• Apple sees this business reaching $10 billion soon

John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool’s board of directors. Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool’s board of directors. Adam Spatacco has positions in Alphabet (A shares), Amazon, and Microsoft. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Alphabet (A shares), Alphabet (C shares), Amazon, and Microsoft. The Motley Fool Australia has recommended Alphabet (A shares), Alphabet (C shares), and Amazon. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

from The Motley Fool Australia https://ift.tt/cASFKRr

The Pilbara Minerals Ltd (ASX: PLS) share price has suffered through plenty of volatility in 2022 so far, but the stock could be set to outperform over the coming 12 months.

The S&P/ASX 200 Index (ASX: XJO) lithium stock reached a high of $3.89 in January before hitting a low of $1.975 in June, marking a 49% tumble between its year-to-date high and low.

Fortunately, it has since recovered most of its losses. The Pilbara Minerals share price is trading at $3.66 right now. That’s 4% higher than it was at the start of this year.  

For context, the ASX 200 has dumped 8% year to date.

And there are plenty more signs pointing to the company being a financial year 2023 winner.

Keep reading to find out what might be in store for the company and why some experts are bullish on its stock.

Could the Pilbara Minerals share price take off in FY23?

Could financial year 2023 (FY23) be the year in which the Pilbara Minerals share price takes off once again? Well, we can’t predict the future, but there are plenty of signs the company could outperform over the near term.

For one, it just reported its maiden profit, bringing in a net profit after tax (NPAT) of $561.8 million for FY22. And it has big expectations for the future.

It believes it will up its production of spodumene concentrate to between 540,000 and 580,000 dry metric tonnes in FY23 – marking a potential 53% year-on-year increase.

However, it also expects its unit operating costs to lift from $555 per dry metric tonne to between $635 and $700 per dry metric tonne.

To top it off, the company believes the lithium deficit could surge to around 1.8 million tonnes by 2040 on a base case basis, likely causing the material’s value to soar.

The company’s not alone in expecting big things from lithium prices. Broker Macquarie believes rising lithium prices will drive the Pilbara Minerals share price higher over the next year.

It has slapped the stock with a $5.60 price target, implying a 54.3% upside, as my Fool colleague Tristan reports.  

However, Credit Suisse is reportedly wary that the company’s costs could surge.

It’s placed a $2.30 price target on Pilbara Minerals shares, representing a potential 36.6% downside.

The post Could the Pilbara Minerals share price really offer more than 50% upside in FY23? appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• Could this new piece of legislation be a boost for ASX lithium shares?
• Here are the 3 most heavily traded ASX 200 shares on Tuesday
• Why is the Novonix share price tumbling 6% on Monday?
• Here are the 3 most heavily traded ASX 200 shares on Monday
• Are Pilbara Minerals shares better value than Allkem right now?

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Macquarie Group Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/njyNfA1

The Imugene Limited (ASX: IMU) share price is on mute after the ASX-listed biotech company reported its results for FY22.

After a wobbly start this morning, the Imugene share price has now stalled at yesterday’s closing price of 24 cents despite a significant jump in the company’s net loss for FY22.

Imugene is a clinical-stage immuno-oncology company developing new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumours.

Let’s take a look at the Imugene results for FY22.

What did Imugene report for FY22?

As mentioned, Imugene is still at a clinical stage, so it’s yet to produce any revenue. Imugene currently receives income from Australian government incentives, which increased from $7.2 million in FY21 to $12.6 million in FY22.

Research and development (R&D) expenses more than doubled from $15.4 million in FY21 to $36.6 million in FY22. General and administrative expenses also lifted, from $10.3 million in FY21 to $14 million in FY22.

Overall, Imugene recorded a net loss of $37.9 million in FY22 compared to a net loss of $18.5 million in FY21.

The current cash balance stands at $99.9 million, so there is ample capital for Imugene to continue with its clinical trials.

What else happened in FY22?

Earlier this month, Imugene provided a positive update as the first patient from the third cohort of the Checkvacc Phase 1 clinical trial had been dosed. The Imugene share price shot up 11% on this news.

Since the update, Checkvacc has progressed to dosing for cohort 3 in triple-negative breast cancer patients. Management plans to disclose the results of these studies later.

Imugene also completed phase 2 in HER-2/Neu overexpressing advanced gastric cancer.

The biotech company also presented new PD1-Vaxx data from non-small cell lung cancer patients at the IASLC 2022 World Conference on Lung Cancer in Vienna, Austria. This data shows early positive signs as the company progresses towards a phase 1b combination study.

What did management say?

Commenting on the FY22 results, Imugene executive chair Paul Hopper said:

As our deep pipeline has continued to advance and strengthen, it provides a wide range of possibilities and opportunities for Imugene moving forward. Financially, the company remains in an enviable position with a long cash runway that allows us to continue our clinical programs unimpeded.

This was reinforced by the $90 million placement conducted early in the financial year alongside a further $5 million raise via a Share Purchase Plan. Both received overwhelming support and we thank those investors that participated.

It appears management is confident in its current financial position, and now it’s a matter of delivering the results. Patience is required in these types of businesses because it could take years for a commercial solution to develop.

What’s next for Imugene?

The plan is for PD1-Vaxx to be tested in combination with atezolizumab (Tecentriq) in patients with non-small cell lung cancer. Imugene locked in a second clinical supply agreement with Roche. The testing will be completed at sites in Australia and the United States.

As for Imugene’s latest technology onCARlytics, the company advised of collaborations with two US-based partners, Celularity and Eureka Therapeutics. This partnership involves investigating the combination of Imugene’s CD19 oncolytic virus technology with T cell therapies being developed by each partner.

Imugene share price snapshot

The Imugene share price has suffered a big fall of 43% in the last 12 months but is looking to make amends with a 4% jump over the last month. The S&P/ASX 200 Index (ASX: XJO) has fallen 7% in the past year and is down 0.3% in the past month.

Imugene has a market capitalisation of around $1.4 billion.

The post Net loss doubles in FY22, so what’s with the Imugene share price today? appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• Here are the top 10 ASX 200 shares today
• The Imugene share price has tumbled 18% since the company’s last update. What’s happening?
• Here are the top 10 ASX 200 shares today
• Here are the 3 most heavily traded ASX 200 shares on Wednesday
• Why Graincorp, Imugene, iSelect, and Mayne Pharma shares are racing higher

Motley Fool contributor Raymond Jang has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/zDbkYEG

The 4DMedical Ltd (ASX: 4DX) share price is trading 23% into the green on Wednesday following a company update.

Investors are rallying the share after it announced a “major success” in the ‘burn pit’ clinical trial. The trial is being conducted by Vanderbilt University Medical Centre, in Nashville in the United States.

What did 4DMedical announce?

Preliminary results indicate that 4DMedical’s XV Technology can detect constrictive bronchiolitis in military veterans, where pulmonary function tests (PFTs) and CT scans have failed to do so.

The XV Technology is a medical imaging platform that uses image-processing methods taken from aerospace engineering to perform deeper respiratory analysis.

Curiously, the background for the trial stems from a pattern of “disabling” respiratory symptoms observed in US military personnel. The symptoms include shortness of breath and coughing, but are severe enough to significantly impact daily function.

It is understood that exposure to toxic chemical fumes when disposing of and burning hazardous/non-hazardous waste was a factor for the personnel during their time serving in the Middle East.

The U.S. military constructed burn pits near bases across the Middle East to dispose of hazardous
and non-hazardous waste.

A wide range of materials, including uniforms, chemicals, tyres, and even medical, animal and human waste, were burned in pits using jet fuel as an accelerant.

It is estimated that 3.5 million Veterans have been exposed to harmful toxins whilst deployed on operations since 2001.

The ‘burn pit’ trial looked at this symptomology and showed that XV Technology is accurate in identifying the constrictive bronchitis.

4DMedical also advised that it has a pre-agreed pricing structure with the Veteran Health Association (VHA). The agreement means the company can offer the procedure at US$171 per scan – without the need for reimbursement.

In the last 12 months, the 4DMedical share price is down more than 61%.

The post Why is the 4DMedical share price rocketing 20% on Wednesday? appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• Why has the 4D Medical share price popped 7% in a month?

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/WsF1IRh

The Best & Less Group Holdings Ltd (ASX: BST) share price is plummeting in midday trade, currently down 15%.

Shares of the iconic clothing retailer are currently trading for $2.295 each after closing on Tuesday at $2.70 a share.

By comparison, the S&P/ASX 200 Index (ASX: XJO) is down 0.32% while the S&P/ASX 200 Consumer Discretionary Index (ASX: XDJ), which Best & Less is a part of, is down just 0.14% at the time of writing

It seems Best & Less’s steep selloff isn’t in step with major market movements. So what’s going on? Let’s investigate.

What’s going on with the Best & Less share price?

There’s no news out of Best & Less today to help make sense of the company’s share price movement.

But yesterday, the retailer posted mixed results in its financial report for FY22. After enjoying an early rally on the back of its results, the company’s shares closed 3% higher on the day.

In its results, Best & Less noted considerable headwinds from COVID-19 that challenged the report’s top and bottom lines.

Both revenue and earnings before interest, taxes, depreciation and amortisation (EBITDA) shrank during the period. Revenue finished at $622 million, down 6.2% year over year, while EBITDA finished at $62.5 million, down 12.7% year over year.

The company announced a final dividend of 12 cents per share. It prompted my colleague Bruce Jackson to mention Best & Less in a roundup post yesterday, noting that the company’s dividend yield of 3.91% was “attractive”.

The company also provided an optimistic update on FY23 so far, reporting total sales were up 38% over the prior corresponding period in the first eight weeks of trading.

But it seems investors are reconsidering the company’s position today.

Best & Less share price snapshot

The Best & Less share price is currently down 44% year to date. Meanwhile, the S&P/ASX 200 Index (ASX: XJO) is down around 8% over the same period.

The company’s market capitalisation is roughly $287 million.

The post Why is the Best & Less share price crashing 15% on Wednesday? appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• ASX dividend windfall continues but it’s not just Woodside and ASX 200 energy stocks splashing the big cash
• Best & Less share price surges 7% on sharp FY22 results

Motley Fool contributor Matthew Farley has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/c8DaGL4

Australian markets are off to a poor start on Wednesday, with the S&P/All Ordinaries Index (ASX: XAO) down 32 basis points to 7,207 at the time of writing.

Meanwhile, the DGL Group Ltd (ASX: DGL) share price has faltered more than 23% in trade this Wednesday following the release of its FY22 results.

DGL Group shares slide in first year of listing

Key takeouts from the All Ords share’s results include:

• Sales revenue of $369.8 million, up 88% on pro-forma FY21 revenue and up 4% on guidance
• Underlying EBITDA of $65.6 million, a gain of 133% on pro-forma FY21, and 1% above prospectus guidance
• Underlying earnings before interest and tax (EBIT) of $48.4 million an increase of 188% on pro-forma FY21 results
• Underlying net profit after tax (NPAT) of $33.6 million, up 197% on pro-forma FY21 profit
• $25.4 million in cash on the balance sheet with $66 million in net bank debt
• Nil dividends paid

What else happened last period for DGL Group?

Growth was observed across all operating segments and throughout the income statement for FY22.

This included chemical manufacturing, warehousing and distribution and environmental solutions, up 141%, 54% and 39% year on year respectively.

Performance was underlined by higher demand for DGL’s services, higher selling prices, and sales revenue contributions from acquired businesses.

In addition, and “following inappropriate public comments expressed by a senior company representative”, the board “engaged culture expert Rhonda Brighton-Hall and her firm MWAH to conduct the independent review”.

“The review found DGL has a diverse workforce and a positive and inclusive culture that is both hard-working and ambitious. Trust and respect were found to be consistent across the business.”

Management commentary

Speaking on the performance, DGL Founder and CEO, Simon Henry said:

Building on our strong momentum in the first half of 2022, we have delivered exceptional results for the 2022 financial year with growth across all earnings metrics. This is a testament to our ability to grow sustainably by offering a fullservice solution for our customers, achieving further economies of scale, and identifying appropriate acquisitions.

All three of our operating divisions performed exceedingly well, benefitting from our deep customer relationships and robust demand as customers continue to onshore their chemical supply chain and hold onto more inventory.

Our deep supplier relationships, capabilities across the supply chain and robust balance sheet mean we are well positioned for another successful year in FY23.

What’s next for DGL Group?

DGL noted many uncertainties in its operations and operating environment looking ahead. With that in mind, it did not provide further guidance for FY23.

Instead, the All Ords share will provide a trading update at its annual general meeting.

The post Why did this ASX All Ords share just crater 23%? appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• Expert names 2 ASX shares to buy for ‘extended, uninterrupted’ good times

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended DGL Group Limited. The Motley Fool Australia has recommended DGL Group Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/JPdqoLa

The Atlas Arteria Group (ASX: ALX) share price is on the move today after the ASX 200 toll road group handed in its first-half 1H22 results.

While the S&P/ASX 200 Index (ASX: XJO) reverses by 0.4% in late morning trade, the Atlas Arteria share price has climbed 0.9% to $8.04.

Atlas Arteria share price rallies as COVID recovery continues 

Here’s a summary of the headline results from Atlas’ first-half report:

• Weighted average traffic was 22.7% above 1H21 and just 1.3% below 1H19
• Toll revenue came in at $53.8 million, up 25% on the prior corresponding period (pcp) of 1H21
• APRR toll revenue grew by 20% on the pcp to €1,290 million
• Statutory net profit after tax (NPAT) soared 184% on the pcp to $117.1 million
• Distribution guidance of 20 cents for 1H22 and a further 20 cents for 2H22

A record full-year distribution of 40 cents would represent an 11% increase over FY21. It puts Atlas shares on a prospective forward dividend yield of 5%.

However, for now, this is simply guidance. Atlas expects to announce its first-half distribution in September. 

On the whole, Atlas’ first-half growth was driven by increased traffic across the APRR network and the easing of COVID restrictions.

APRR is the second-largest toll road network in France and the fourth-largest motorway group in Europe. 

Atlas holds a 31.14% indirect interest in APRR, which brings in the lion’s share of the group’s revenue. In the first half, APRR contributed to 90% of Atlas Arteria’s revenue.

What else happened in 1H22?

APRR traffic was the highlight, increasing by 23.4% on the pcp on the back of a busy winter holiday period, strong domestic tourism, and reduced COVID restrictions across Europe. Notably, these traffic levels were 2.3% higher than pre-COVID levels of 1H19.

During the half, APPR expanded its network with the addition of the A79 motorway in southern France. Construction of the 88km road upgrade is expected to finish in late 2022, with tolling to commence on opening.

The roll-out of electric vehicle charging stations across the APRR network continues. Around 70% of motorway service areas are now equipped with high or very high power terminals. 

At Dulles Greenway in the United States, Atlas’ second-largest contributor of revenue, traffic increased by 12.3% on the pcp. However, traffic remained 34% lower than 1H19 due to the delayed return to office-based work.

What did management say?

Commenting on the results, Atlas Arteria CEO Graeme Bevans said:

Atlas Arteria delivered a strong result during the period, driven by improved operating conditions across France, Germany and the USA.

Atlas Arteria is well positioned in the current high inflationary environment. In 2022 we are absorbing some inflationary impacts in our costs given higher pricing, however with toll prices at APRR, ADELAC and Warnow Tunnel directly linked to inflation and a high proportion of fixed debt across the portfolio, securityholders stand to benefit from 2023 onwards.

What’s next?

Commenting on the outlook, Atlas noted that its financial performance was positively correlated to inflation. Thus, shareholders stand to benefit during a high inflationary environment.

This is because most of the toll prices across Atlas’ network are directly linked to inflation. In other words, it can hike up toll prices as inflation soars.

Rounding out its outlook statement, Atlas believes it has strong organic growth potential within the current portfolio and continues to focus on improving average concession life.

Atlas Arteria share price snapshot

Since Atlas benefits from rising inflation, the Atlas Arteria share price has bucked the broader ASX 200 this year to punch in strong gains.

In the last six months, the Atlas Arteria share price has jumped 24%. Zooming out further, Atlas shares are up 17% in the last year.

The post Atlas Arteria share price drives higher on record dividend guidance appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• Here are the top 10 ASX 200 shares today
• Up 4% today, could this ASX 200 share finally receive a takeover bid?

Motley Fool contributor Cathryn Goh has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/Lw1x97p

The Harvey Norman Holdings Limited (ASX: HVN) share price is in the red after the company posted its earnings for financial year 2022.

Shares in the S&P/ASX 200 Index (ASX: XJO) electronics and homewares retailer opened at $4.33 each this morning and slipped to an intraday low of $4.23 a share.

At the time of writing, the Harvey Norman share price is $4.24, 2.08% lower than its previous close.

Harvey Norman share price falls on FY22 earnings

Here are the key takeaways from the ASX 200 giant’s full-year results:

• Sales came to $9.5 billion – a 1.7% fall on that of the prior corresponding period (pcp)
• Profit after tax slipped 3.6% to $811.5 million
• Earnings before interest, tax, depreciation, and amortisation (EBITDA) slumped 1.4% to $1.4 billion
• Basic earnings per share (EPS) came to 65.13 cents
• Declared a 17.5 cent fully franked final dividend, bringing its full-year payout to 37.5 cents – a 7.1% improvement on that of FY21

Harvey Norman revealed 25% of its pre-tax profits, excluding property revaluations, last financial year came from its overseas retail stores.

In Australia, its franchisees were impacted by COVID-19-induced lockdowns in the first half. The segment’s pre-tax profit fell 12% year on year to $628.19 million despite it posting a record second half.

The company’s property segment closed the period with assets exceeding $3.7 billion and a $366.5 million pre-tax profit – a 25.7% improvement.

What else happened in FY22?

The retailer opened three new Australian company-owned stores in FY22, located in Murwillumbah, Port Pirie, and Charters Towers. It also opened a new company store in Malaysia and a commercial outlet in New Zealand.

The Harvey Norman share price tumbled 32% over the 12 months to 30 June.

What did management say?

Harvey Norman chair Gerry Harvey commented on the company’s results, saying:

Our omni channel strategy continues to deliver, our balance sheet is strong, our cash reserves are solid and we continue to maintain a low net debt to equity ratio of 10.31%. With experienced management, we have grown our integrated retail, franchise, property, and digital business across eight countries to nearly $10 billion in system sales.

Cash conversion in FY22 has significantly improved compared to FY21 predominantly due to a $53.43 million increase in net cashflows from operating activities, from $543.87 million in FY21 to $597.30 million for FY22. The solid cash flows generated from operating activities this year will enable us to further enhance and promote our brand locally and overseas to grow our businesses, refurbish our existing stores and invest in new property acquisitions and pay down external debt.

What’s next?

The company didn’t provide any new earnings guidance today. However, it outlined a number of expectations for the current financial year and provided a trading update.

It plans to open two new franchised complexes in Australia and relocate another to a freehold property in FY23. Overseas, it opened its 16th company-operated store in Ireland in July and expects to ramp up its offshore expansion plans with four more company-operated stores in New Zealand, Malaysia, and Croatia.

The period from 1 July to 29 August saw its sales grow in all regions except Ireland and Northern Ireland. They saw respective decreases of 1% and 10.2% on those of the pcp.

Australian sales, meanwhile, lifted 10.7%, while those of Malaysia and Slovenia and Croatia rose 108% and 12.2% respectively.

Harvey Norman share price snapshot

The Harvey Norman share price has had a rough trot of late.

It has fallen 14% since the start of the year. It’s also currently 21% lower than it was this time last year.

For comparison, the ASX 200 has sunk 8% year to date and 7% over the last 12 months.

The post Harvey Norman share price slips despite FY22 sales nearing $10b appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#43B02A”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#43B02A”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• 5 things to watch on the ASX 200 on Wednesday
• Why are ASX 200 retail shares having such a stellar run today?
• 2 ASX 200 dividend shares with ~7%+ yields that experts rate as buys
• What’s impacting ASX 200 retail shares today?
• 2 ASX 200 dividend shares analysts rate as buys

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Harvey Norman Holdings Ltd. The Motley Fool Australia has positions in and has recommended Harvey Norman Holdings Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/CUX6zZA

The MoneyMe Ltd (ASX: MME) share price is on ice today following a company-requested trading halt on Tuesday.

Aside from this, the company also posted its FY22 full-year results before the open today as well.

The MoneyMe share price is resting at 69 cents, down more than 68% this year to date.

Why is the MoneyMe share price halted?

The company notes it requested the trading halt of its securities for a planned equity raise.

It is undertaking a fully underwritten placement to raise $20 million. To do this, it will issue 40 million new fully-paid ordinary shares.

MoneyMe will issue the placement shares at a fixed price of 50 cents apiece, representing a 28.1% discount to the last close price on Monday – just before the halt.

Specifically, it hopes to raise approximately $17.84 million through the issue of approximately 35.7 million shares in an unconditional offer.

Then, it wants to raise the additional $2.16 million through a conditional placement that will require shareholder approval.

“The proceeds from the equity raising will be utilised for equity subordination requirements in MoneyMe’s warehouse facilities to support continued loan book growth, and payment of associated upfront commissions to brokers,” the company said.

“In its normal course of business, MoneyMe will continue to explore opportunities to expand new and existing debt capital facilities to support its balance sheet and loan receivables growth,” it added.

The MoneyMe share price is expected to remain in a trading halt until Thursday, whilst the equity raise is being completed.

MoneyMe shares remain down more than 66% in the past 12 months of trade.

The post MoneyMe share price halted amid results and cap raise appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• Why the Amazon share price slumped on Tuesday
• Here’s why analysts have slapped buy ratings on these ASX shares
• Praemium share price spikes hard as profit soars in FY22
• Why Bitcoin, Ethereum, and Dogecoin are falling today
• Webjet share price ascends 11% amid profitable start to FY23

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/Vgnt4A8